Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 21,615

Document Document Title
WO/2018/006750A1
Provided is a secretory protein sDSS1 of a higher primate. The protein can be detected in human blood serum and cerebrospinal fluid. The sDSS1 protein can bind, under non-enzymatic conditions, with an oxidized protein to form a polymer, ...  
WO/2018/006881A1
A recombinant receptor and an application thereof. The recombinant receptor comprises: a cellular immune-checkpoint molecular segment; an immune stimulator molecular segment; and a T-cell receptor zeta chain.  
WO/2018/006269A1
Disclosed are an acridine-marker conjugate and a preparation method thereof, and a chemiluminescence immunoassay kit. The acridine-marker conjugate comprises an acridine substituent, a connecting vector, a bifunctional crosslinking agent...  
WO/2018/006882A1
Provided in the present invention is an antibody for anti-claudin 18A2 and an immune effector cell targeting claudin 18A2. Also provided are methods for inducing cell death and treating tumours.  
WO/2018/006268A1
Disclosed are an acridine-marker conjugate, preparation method thereof, and a chemiluminescence kit. The acridine-marker conjugate comprises an acridine substituent, a polyamino acid, and a protein to be marked, connected in that order. ...  
WO/2018/006264A1
Disclosed are an acridine marker conjugate and a preparation method therefor and a chemiluminescent kit. The acridine marker conjugate comprises an acridine substitute, a carrier protein and a protein to be marked sequentially connected....  
WO/2018/009624A1
The present invention discloses heterodimers comprising endoglin-Fc and ALK1-Fc, or heterodimers comprising endoglin-Fc and ALK2-Fc. The Fc domains can include amino acid mutations that promote heterodimer formation. In certain aspects, ...  
WO/2018/006880A1
A transgenic lymphocyte, a construct, and a therapeutic composition for treating cancer. The transgenic lymphocyte has a silenced cellular immune-checkpoint and expresses a recombinant receptor. The recombinant receptor comprises: a cell...  
WO/2018/003983A1
The invention provides a drug and a method for producing same, said drug having as an active ingredient a conjugate, in which an hANP peptide is bound to a sugar chain (N297 sugar chain) that binds to Asn 297 of an Fc-containing molecule...  
WO/2018/004281A2
Disclosed are a tranexamic acid-peptide having a skin whitening effect and skin whitening activity with excellent thermal stability and time stability, which is capable of inducing return to healthy skin and whitening effect through skin...  
WO/2018/005617A2
Disclosed herein are compositions and formulations containing a TATĸ-CDKL5 fusion protein. Also disclosed are methods of producing a TATĸ-CDKL5 fusion protein from vectors containing a TATĸ-CDKL5 cDNA and methods of transducing cells ...  
WO/2017/222593A1
The present disclosure relates to compositions and methods relating to chimeric antigen receptor (CAR) polypeptides and methods relating thereto. In one embodiment, the present disclosure relates to engineered cells having chimeric antig...  
WO/2017/219916A1
Provided are a chimeric immune inhibitory checkpoint receptor molecule, a nucleic acid encoding the same, a construct, expression vector and transformed cell containing the nucleic acid, and a pharmaceutical use thereof. The chimeric imm...  
WO/2017/222330A1
The present application provides a single-chain blood coagulation factor VIII including a B region which is partially deleted to contain at least four glycosylation sites, but not a heavy chain, a light-chain, and a region to be cleaved ...  
WO/2017/222034A1
The present invention is a modified fibroin including a domain sequence represented by formula 1: [(A)n motif-REP]m, wherein, compared to a fibroin derived from nature, the domain sequence contains an amino-acid sequence that locally inc...  
WO/2017/221850A1
The present invention addresses the problem of providing a means for enhancing the function of cytotoxic T cells used for cytotoxic T-cell therapy. Provided by the present invention are: an artificial T-cell activation molecule that incl...  
WO/2017/217460A1
A fusion protein containing at least two proteins, said fusion protein being characterized in that the at least two proteins are fused to each other through a peptide linker having the following amino acid sequence: Xm(PYn)qPZr. In the a...  
WO/2017/218355A1
Provided herein are new compositions and methods to target and deliver agents to pathological areas by utilizing multifunctional compounds. These compounds include three or more domains: (i) a vimentin-binding peptide, (ii) a linker, and...  
WO/2017/218677A2
Compositions and methods for detection of anti-citrullinated protein antibodies (ACPAs) in rheumatoid arthritis (RA) patients. Patient samples known or suspected of containing ACPAs were probed against citrullinated proteins, and antibod...  
WO/2017/215619A1
Provided are a fusion protein producing a point mutation in a cell, and preparation and use thereof. The fusion protein includes or is formed by a cytosine deaminase and Cas enzyme in which the nuclease activity is deficient but the heli...  
WO/2017/217453A1
Provided is a cellulase having high binding ability to cellulose substrates. Cellulase having a xylanase carbohydrate binding module (CBM).  
WO/2017/218867A1
The present disclosure provides fusion proteins comprising Mycobacterium tuberculosis (Mtb) antigens, nucleic acid molecules encoding the same, vectors comprising nucleic acid molecules, compositions comprising the same, and methods of e...  
WO/2017/218897A1
Disclosed herein are multifunctional antigen-binding proteins comprising at least one multifunctional recombinant protein scaffold and at least one antigen-specific binding domain. Polynucleotides encoding the multifunctional antigen-bin...  
WO/2017/214151A1
The disclosure provides constructs comprising a first fusion protein, a second fusion protein, and a linker, wherein the first fusion protein and the second fusion protein each include an affinity reagent and a reactive enzyme, and the l...  
WO/2017/214024A1
The invention relates generally to a silvestrol molecule activated with a leaving group. The invention further relates generally to an antibody-drug conjugate comprising an antibody conjugated by a linker to one or more silvestrol drug m...  
WO/2017/214076A1
The present invention describes rhomboid protease inhibitors having high specificity and inhibition characteristics providing novel antibiotics, anti-malarial pharmaceutical agents, and provides a strategy for designing RiBns (rhomboid-i...  
WO/2017/207540A1
The present invention relates to novel anthracycline derivatives comprising two oxazolidine cycles and the preparation of said anthracycline derivatives. Furthermore, antibody-drug conjugates (ADCs) comprising the novel anthracycline der...  
WO/2017/210288A1
There is disclosed derivatives of amanitin conjugated to a targeting antibody to form an ADC (antibody drug conjugate).  
WO/2017/209274A1
The present invention provides an adjuvant that can induce immunostimulation, particularly T cell immunostimulation. The present invention provides an adjuvant that can particularly induce antigen-specific immunostimulation, particularly...  
WO/2017/209122A1
[Problem] The present invention addresses the problem of developing a method for controlling a target RNA. [Solution] Provided is a fusion protein containing: a functional domain that improves the protein expression from mRNA; and a PPR ...  
WO/2017/210077A1
Prodrug formulations of insulin and insulin analogs are provided wherein the insulin peptide has been modified by linkage of the carboxy terminus of the B chain to the N-terminus of the A chain via a metastable dipeptide to form an inact...  
WO/2017/210246A2
Conjugates of an active agent attached to a targeting moiety via a penicillamine linker, and particles comprising such conjugates have been designed. Such conjugates and particles can provide increased stability and improved temporospati...  
WO/2017/205309A1
Insulin dimers and insulin analog dimers that act as partial agonists at the insulin receptor are disclosed.  
WO/2017/202776A1
The present invention is situated in the field of multimers used for targeted therapies. More particularly, the invention relates to methods for preparing multifunctional heteromultimeric protein complexes with a defined ratio of functio...  
WO/2017/202172A1
Provided is a modified transferrin DNA binding domain, wherein the transferrin is lactoferrin LTF, serum transferrin TF, melanotransferrin MTF or ovotransferrin OTF. The N-terminus of each transferrin has a homologous DNA binding domain,...  
WO/2017/202394A1
A fusion protein used for preventing and treating Alzheimer's disease, a preparation method therefor, and an application thereof. The fusion protein comprises the extracellular domain of human p75NTR (p75 neurotrophin receptor) (p75NTR-E...  
WO/2017/201579A1
The invention relates to a vaccine comprising live attenuated recombinant alphavirus comprising mutated capsid protein. The invention also relates to a method of preventing a subject from contracting an alphaviral infection that would ot...  
WO/2017/204729A1
The present invention relates a to method for preparing a biological sample for use in an immunolabeling process. The invention also relates to corresponding kits for use in the immunolabeling process. The method comprises the following ...  
WO/2017/202933A1
The present invention relates to a synthetic compound comprising at least one effector moiety and at least one binder moiety, wherein the effector moiety is associated to the binder moiety, and wherein further the effector moiety compris...  
WO/2017/205651A1
This invention provides a fusion protein, the sequence of which, commencing at the N-terminus of the fusion protein, is identical to the sequence of amino acids in: (a) an extracellular domain of a human Notch1 receptor protein, followed...  
WO/2017/200461A1
The present embodiments relate to antibody binding nanofibrils obtainable by co-fibrillation of carrier proteins and carrier –Z fusion proteins at a molar ratio selected within an interval of from 1:0.20 to :0.90. The antibody binding ...  
WO/2017/201432A3
Fusion proteins comprising IL2 and IL2Rβ (e.g., CIRB), IL2, IL2Rβ and IL21R (e.g., CIRB21), and/or comprising IL2, IL2Rβ, and CD28 (e.g., CIRB28); natural killer (NK) cells that express the fusion proteins and methods of use thereof, ...  
WO/2017/201432A2
Fusion proteins comprising IL2 and IL2Rβ (e.g., CIRB), IL2, IL2Rβ and IL21R (e.g., CIRB21), and/or comprising IL2, IL2Rβ, and CD28 (e.g., CIRB28); natural killer (NK) cells that express the fusion proteins and methods of use thereof, ...  
WO/2017/197231A1
Provided herein is a CD40L-Fc fusion protein and methods of using the fusion protein in the treatment of cancer comprising administering the CD40L-Fc fusion protein or the CD40L-Fc fusion protein in combination with one or more immune ch...  
WO/2017/195749A1
Provided are a novel CAR, CAR T-cells, and the like which are effective in treating diseases such as cancer. This chimeric antigen receptor is selected from the group consisting of chimeric antigen receptors A-F. The CAR T-cells express ...  
WO/2017/196954A1
Compounds useful as fluorescent or colored dyes are disclosed. The compounds have the following structure (I), including stereoisomers, salts and tautomers thereof, wherein R1, R2, R3, L1, L2, L3, L4, L5, M, m and n are as defined herein...  
WO/2017/192580A1
The present invention provides plant-made elafin-Fc fusion proteins for treating inflammatory diseases, e.g., inflammatory lung diseases. In certain embodiments, the fusion proteins comprise one or more point mutations, which confer impr...  
WO/2017/191817A1
The present invention provides a means with which it is possible to efficiently produce a fused substance of an Fc protein and a target substance (for example, a peptide). Specifically, the present invention provides an azide group-conta...  
WO/2017/190684A1
Disclosed are an interleukin combination or fusion protein for preventing and/or treating malignant tumours, and various products prepared with same and the use thereof.  
WO/2017/192536A1
The present disclosure generally relates to chimeric antigen receptors, more specifically to chimeric antigen receptor compositions and methods for use of the same. The present disclosure also provides for nucleic acid molecules and expr...  

Matches 1 - 50 out of 21,615